Select Page

‘Big Bang Theory’ Star Kate Micucci Reveals Lung Cancer Despite Never Smoking—How Can That Happen?
“Kate Micucci, known for her work on “The Big Bang Theory,” has lung cancer, according to a TikTok video shared Tuesday with her followers. “Hey everybody, this is not a TikTok, it’s a ‘sick tok,’” Micucci, 43, told viewers. “I’m in the hospital but it’s because I had lung cancer surgery yesterday.” Micucci said her care team found the cancer early—but that it was still an unexpected discovery. “It’s pretty weird because I’ve never smoked a cigarette in my life,” she said, “so it was a surprise, but also I guess it happens.””

Explained: Radon a silent killer and second leading cause of lung cancer with 21,000 annual deaths
“Dr Minish Jain, Director of Medical Oncology Ruby Hall Clinic Pune told News9, “It is a naturally occurring radioactive gas, inert, colourless, odourless, naturally present in the atmosphere in trace amounts. This radon gas gets trapped indoors through cracks and other holes in the foundation and its exposure over time increases the risk of lung cancer.””

“DECEMBER 15, 20243 – TALLAHASSEE, FL – Rep. Karen Gonzalez Pittman (R-Tampa) and Sen. Alexis Calatayud (R- Miami) filed bills today (HB 885 and SB 964) that will allow more Floridians to access biomarker testing, which has become an increasingly important part of cancer care in recent years due to its significant impact in improving survivorship and quality of life. The bill will ensure more patients have the opportunity to benefit from this game-changing testing.”

“The IASLC Cancer Care Team Award honors multidisciplinary teams as nominated by the patients they serve. Exceptional care teams offer the patient seamless and informed communication and an individualized treatment plan based on not just the patient’s needs but the patient’s wishes. The Cancer Care Team Award aims to highlight this kind of worldwide outstanding care. The IASLC Cancer Care Team Award was established in memory of Marilyn Holman, who passed away from lung cancer in 2016. By recognizing Cancer Care Teams across the globe, we hope to spread awareness and speak to the outstanding care that is possible for all lung cancer patients from the time of diagnosis through treatment.”

Take Our Lung Cancer Risk Quiz and Determine Your Eligibility For Screening
“Thanks to the latest advances in medical technology, there is new hope for patients and families at risk for lung cancer. Our screening eligibility quiz will let you know if you should talk to your doctor about being screened for lung cancer via low-dose CT scan. Screening is key to early detection — when lung cancer is diagnosed at an early stage it is more likely to be curable.”

Camrelizumab/Chemo Boosts Responses Vs Chemo Alone in Resectable NSCLC
“Combining camrelizumab and chemotherapy resulted in more robust pathological complete response (pCR) rates compared with chemotherapy alone in those with resectable stage IIIA or IIIB non–small cell lung cancer (NSCLC), according to findings from the phase 2 TD-FOREKNOW trial (NCT04338620).”

Attorney General Jason Miyares says insurance companies can’t deny cancer treatment to patients
“HAMPTON, Va. — News that you have cancer makes you think of your options. On Friday, Attorney General Jason Miyares issued an opinion about one particular treatment that isn’t always easy for cancer patients to receive.”

Andre Braugher died of lung cancer, publicist says
“Acclaimed actor Andre Braugher died of lung cancer, his publicist confirmed to CBS News on Thursday. Braugher’s publicist, Jennifer Allen, had previously said that the actor died on Monday, Dec. 11 “after a brief illness.” His death was announced Tuesday night.”

Prognostic Factors and Outcomes in Advanced Stage Lung Cancer Patients with COVID-19 Omicron Variant Infection
“This study underscores the importance of prompt intervention and early diagnosis for lung cancer patients infected with the COVID-19 Omicron variant. Lower oxygen saturation, decreased lymphocyte/neutrophil ratio on day 7, and diffuse lung lesions on CT scans were associated with worse outcomes. Clinicians should prioritize timely and comprehensive management to improve survival rates in this population.”

FDA Grants Priority Review to Tarlatamab in Advanced SCLC
“Encouraging results from DeLLphi-301 trial (NCT05060016) demonstrated antitumor activity, durable response, and promising survival outcomes in patients with previously treated small cell lung cancer (SCLC) when given tarlatamab (AMG 757). A Prescription Drug User Fee Act (PDUFA) target action date was set for June 12, 2024, based on this designation. With this FDA acceptance, there is potential for a quicker approval process, highlighting the urgency and unmet need for new treatment options in advanced SCLC.”

Aerobic Exercise, Tai Chi Improved Sleep in Patients With Lung Cancer
“According to a study published in JAMA Oncology, patients with advanced lung cancer saw improvements in all circadian rhythm, physical function, sleep, and psychological distress when they consistently took part in aerobic exercise (AE) and tai chi (TC) as part of their survivorship care.”

Liquid Biopsy Predicts Immunotherapy Response and Toxicity in Patients with Advanced Lung Cancer
“Newswise — Using a “liquid biopsy” to study genetic material from tumors shed into the bloodstream together with immune cells could help clinicians predict which patients with advanced lung cancers are responding to immunotherapies and which patients may develop immune-related side effects several months later, according to research directed by investigators at the Johns Hopkins Kimmel Cancer Center, the Bloomberg Kimmel Institute for Cancer Immunotherapy and Allegheny Health Network Cancer Institute in Pittsburgh.”

Moderna: to evaluate mRNA in lung cancer
“Merck and Moderna announced on Monday the launch of their Phase III clinical trial to evaluate the combination of immunotherapy and messenger RNA (mRNA) technology in the treatment of lung cancer. The two partners specify that the study plans to combine Keytruda, Merck’s flagship antibody, with Moderna’s V940 vaccine (mRNA-4157), designed to teach patients’ immune systems to identify and destroy cancer cells. The trial – dubbed ‘INTerpath-002’ – is scheduled to enroll 1,089 previously operated patients with stage II, IIIA or IIIB non-small-cell cancer. Merck and Moderna stress that recruitment has already begun in Australia, before being launched at 38 different sites in 13 other countries.”


Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer